Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study)

Schouten, 2002, Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma, Cancer, 94, 2698, 10.1002/cncr.10541 LEVY, 1998, Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma, J Urol, 159, 1163, 10.1016/S0022-5347(01)63541-9 Motzer, 2020, Kidney cancer, version 1.2021: Featured updates to the nccn guidelines, JNCCN J Natl Compr Cancer Netw, 18, 1160, 10.6004/jnccn.2020.0043 Vickers, 2013, Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: Results from the international metastatic renal cell carcinoma database consortium, Clin Genitourin Cancer, 11, 311, 10.1016/j.clgc.2013.04.012 Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol Cancer Clin Trials 2013; 36: 620-4. doi:10.1097/COC.0b013e31825d59db. Hoshi, 2002, Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: Results in 42 patients, Int J Urol, 9, 618, 10.1046/j.1442-2042.2002.00531.x Sheehan, 2003, Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control, J Neurosurg, 98, 342, 10.3171/jns.2003.98.2.0342 Gaspar, 2000, Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases, Int J Radiat Oncol Biol Phys, 47, 1001, 10.1016/S0360-3016(00)00547-2 Weltman, 2000, Radiosurgery for brain metastases: A score index for predicting prognosis, Int J Radiat Oncol Biol Phys, 46, 1155, 10.1016/S0360-3016(99)00549-0 Lorenzoni, 2004, Radiosurgery for treatment of brain metastases: Estimation of patient eligibility using three stratification systems, Int J Radiat Oncol, 60, 218, 10.1016/j.ijrobp.2004.02.017 Sperduto, 2008, A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database, Int J Radiat Oncol Biol Phys, 70, 510, 10.1016/j.ijrobp.2007.06.074 Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, et al. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncol 2017;20(12), 1652–60, 2017. doi: 10.1093/neuonc/noy099. Sato Y, Yamamoto M, Serizawa T, Yamada K ichiro, Higuchi Y, Kasuya H. A graded prognostic model for patients surviving 3 years or more (GPM ≥ 3Ys) after stereotactic radiosurgery for brain metastasis. Radiother Oncol 2021;156:29-35. doi:10.1016/j.radonc.2020.11.024. Soike, 2018, Initial brain metastasis velocity: does the rate at which cancers first seed the brain affect outcomes?, J Neurooncol, 139, 461, 10.1007/s11060-018-2888-3 Sperduto, 2010, Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients, Int J Radiat Oncol, 77, 655, 10.1016/j.ijrobp.2009.08.025 Sperduto, 2012, Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 30, 419, 10.1200/JCO.2011.38.0527 Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, et al. Estimating survival for renal cell carcinoma patients with brain metastases: An update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 2018;20:1652-60. doi:10.1093/neuonc/noy099. Yamamoto, 2012, Subclassification of Recursive Partitioning Analysis Class II Patients With Brain Metastases Treated Radiosurgically, Int J Radiat Oncol, 83, 1399, 10.1016/j.ijrobp.2011.10.018 Yamamoto, 2013, A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: Comparing treatment results for 1–4 vs ≥ 5 tumors, J Neurosurg, 118, 1258, 10.3171/2013.3.JNS121900 Yamamoto, 2013, Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases, J Neurooncol, 111, 327, 10.1007/s11060-012-1019-9 Higuchi, 2009, Three-Staged Stereotactic Radiotherapy Without Whole Brain Irradiation for Large Metastatic Brain Tumors, Int J Radiat Oncol Biol Phys, 74, 1543, 10.1016/j.ijrobp.2008.10.035 Yamamoto M, Higuchi Y, Serizawa T, Kawabe T, Nagano O, Sato Y, et al. Three-stage Gamma Knife treatment for metastatic brain tumors larger than 10 cm3: A 2-institute study including re-analyses of earlier results using competing risk analysis. In: Journal of Neurosurgery 2018;129:77-85. doi:10.3171/2018.7.GKS181392. Mekhail, 2005, Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma, J Clin Oncol, 23, 832, 10.1200/JCO.2005.05.179 Yamamoto, 2019, Applicability and limitations of a recently-proposed prognostic grading metric, initial brain metastasis velocity, for brain metastasis patients undergoing stereotactic radiosurgery, J Neurooncol, 143, 613, 10.1007/s11060-019-03199-8 Frisk, 2012, Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden, Br J Cancer, 106, 1850, 10.1038/bjc.2012.163 van Ruitenbeek, 2021, Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery, J Neurooncol, 153, 527, 10.1007/s11060-021-03793-9 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Matsui, 2020, Current multimodality treatments against brain metastases from renal cell carcinoma, Cancers (Basel), 12, 1, 10.3390/cancers12102875 Motzer, 2018, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Motzer, 2015, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Motzer, 2019, Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Rini, 2019, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714